Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT.

In a Phase 1b trial in Crohn’s patients with previous surgery, TAK-018 was well tolerated and showed a trend toward reducing AIEC abundance in stools and delaying endoscopic recurrence (though patient numbers were small) [ 42 ].

also in 53,322 other papers